Refractory Acute Myeloid Leukemia Clinical Trial
Official title:
A Phase 2, Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults Unfit for Intensive Chemotherapy With Relapsed or Refractory AML or Higher-Risk Myelodysplastic Syndromes
Verified date | July 2022 |
Source | BioSight Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
An open label multi center study to assess the safety and efficacy of BST-236 as single agent in adult patients unfit for standard therapy with Acute Myeloid Leukemia (AML) or higher-risk (HR) Myelodysplastic Syndromes (MDS) who fail to respond or relapsed following first line therapy. Approximately 20 adult patients with relapsed and/or refractory AML and approximately 20 adult patients with relapsed and/or refractory HR MDS, will be enrolled into the study. Patients will be treated with 1-2 induction courses and 2-4 maintenance courses. All patients will be followed for 1 year in the study and additional 1 year post study follow-up.
Status | Active, not recruiting |
Enrollment | 40 |
Est. completion date | March 14, 2024 |
Est. primary completion date | December 14, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | 1. Documented diagnosis of MDS, according to World Health Organization (WHO) classification and Revised International Prognostic Scoring System (IPSS-R) overall score = 4.5 Or Diagnosed AML according to the 2016 revision to the WHO classification of myeloid neoplasms and acute leukemia: =20% blasts in peripheral blood or bone marrow 2. Adult =18 years of age 3. MDS relapse following treatment with azacitidine or decitabine Or MDS failure to achieve complete or partial response or stable disease with hematologic improvement after at least 4 cycles of azacitidine or decitabine, all within the last 1 year Or MDS progression while on azacitidine or decitabine treatment irrespective of the number of cycles the patient has received Or AML relapse after initial CR/CRi/CRh following treatment with: azacitidine, decitabine, Low-Dose Ara-C (LDAC) , venetoclax+HMA, or venetoclax+LDAC Or AML failure to achieve CR, CRh or CRi following at least 4 cycles of azacitidine or decitabine or 2 cycles of venetoclax+HMA or venetoclax+LDAC within the last 1 year. Or AML progression while on azacitidine, decitabine, LDAC, venetoclax+HMA, venetoclax+LDAC, irrespective of the number of cycles the patient has received. 4. Not able to receive an allogeneic bone marrow transplantation (BMT) at the time of study enrolment. 5. Not eligible for intensive chemotherapy; 1. Age =75 years Or 2. Age =18 years with at least one of the following comorbidities: 3. Significant heart or lung comorbidities, as reflected by at least one of the following: 4. Left ventricular ejection fraction (LVEF) =50% 5. Lung diffusing capacity for carbon monoxide (DLCO) =65% of expected 6. Forced expiratory volume in 1 second (FEV1) =65% of expected 7. Chronic stable angina or congestive heart failure controlled with medication 8. Other comorbidity or conditions that the Investigator judges as incompatible with intensive chemotherapy, which must be documented 9. ECOG=2 6. Creatinine clearance (estimated by the Modification of Diet in Renal Disease (MDRD) equation or measured by 24 hours urine collection) =45 mL/min 7. Liver enzymes (aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =2.5 times the upper limits of normal (ULN), unless attributed to leukemia (in AML patients) 8. Total bilirubin =3 XULN unless due to Gilbert disease 9. Eastern Cooperative Oncology Group (ECOG) performance status = 2 10. Women of reproductive potential must have a negative serum pregnancy test within 48 hours prior to the first day of any BST-236 treatment course 11. Women of reproductive potential must use two forms of effective birth control methods starting from at least 1 month prior to BST-236 first dose and until 3 months following the last BST-236 administration day (acceptable methods of birth control in this study include: surgical sterilization, intrauterine devices, oral contraceptives, contraceptive patch, long-acting injectable contraceptives, or double-barrier method condom or diaphragm with spermicide) 12. Male subjects must agree to refrain from unprotected sex and sperm donation from initial study drug administration until 3 months following the last dose of study drug 13. Subject must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures 14. Patient must be able to adhere to the study visit schedule and other protocol requirements Exclusion Criteria: 1. MDS or AML evolving from a pre-existing myeloproliferative neoplasm (MPN) 2. MDS/MPN including chronic myelomonocytic leukemia (CMML), atypical chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia (JMML) and unclassifiable MDS/MPN 3. Acute promyelocytic leukemia 4. Previous treatment for AML or MDS with drugs other than HMA or LDAC or combinations of venetoclax with either HMA or LDAC 5. Previous allogeneic hematopoietic stem cell transplantation (HSCT) or solid organ transplantation 6. Participation in a previous clinical trial involving use of an investigational drug within 30 days or at least 5 half-lives of tested drug (whichever is shorter) of study day 1 7. Peripheral White Blood Cell (WBC) count >30,000 /µL in the 48 hours prior to first BST-236 dose administration. Hydroxyurea administration or leukapheresis is permitted to meet this criterion 8. Administration of HMA, LDAC, or venetoclax within 14 days prior to Study Day 1 9. Previous treatment with cytarabine at a dose higher than 20 mg/ m2/d 10. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment) 11. Any medical or surgical condition, presence of laboratory abnormalities or psychiatric illness that may preclude safe and complete study participation based on the Investigator's judgment 12. Diagnosis of malignant disease (other than AML) within the previous 12 months (excluding basal cell carcinoma of the skin without complications, "in-situ" carcinoma, or other local malignancy excised or irradiated with a high probability of cure and not treated with systemic or topical chemotherapy) 13. Surgical procedure, excluding central venous catheter placement or other minor procedures (e.g. skin biopsy) in the 14 days prior to first BST-236 dose administration 14. History of allergic reactions attributed to compounds of similar chemical composition as BST-236 and/or cytarabine 15. Life expectancy shorter than 3 months attributed to any known medical condition other than AML/MDS 16. In 12 leads ECG, corrected QT interval (QTc)>480msec or history of QT prolongation or Torsades de pointes |
Country | Name | City | State |
---|---|---|---|
United States | University of Virginia Cancer Center | Charlottesville | Virginia |
United States | The University of Texas MD Anderson Cancer center | Houston | Texas |
United States | Seattle Cancer Care Alliance | Seattle | Washington |
United States | Ochsner LSU Health Shreveport - Academic Medical Center | Shreveport | Louisiana |
Lead Sponsor | Collaborator |
---|---|
BioSight Ltd. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | CR rate | In AML patients -The proportion of patients who achieve a CR per the IWG 2006 Criteria | To be assessed 5 months after the last patient was enrolled to the study | |
Primary | Overall response rate (ORR) | In MDS patients -Overall response rate (ORR), defined as the proportion of patients who achieve a CR or PR per proposal for modification of the International Working Group (IWG) criteria for MDS, 2006 | To be assessed 5 months after the last patient was enrolled to the study |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02890329 -
Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
|
Phase 1 | |
Active, not recruiting |
NCT04975919 -
Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 2 | |
Terminated |
NCT02882321 -
Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT03214562 -
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03289910 -
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
|
Phase 2 | |
Completed |
NCT02756572 -
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
|
Phase 2 | |
Completed |
NCT02509546 -
8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT03683433 -
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
|
Phase 2 | |
Completed |
NCT02551718 -
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
|
N/A | |
Completed |
NCT02070458 -
Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Terminated |
NCT03557970 -
JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT03661307 -
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
|
Phase 1/Phase 2 | |
Recruiting |
NCT03629171 -
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05396859 -
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
|
Phase 1 | |
Terminated |
NCT03067571 -
Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
|
Phase 2 | |
Completed |
NCT04146038 -
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
|
Phase 2 | |
Suspended |
NCT03128034 -
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04207190 -
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Recruiting |
NCT04047641 -
Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04493099 -
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML
|
Phase 1/Phase 2 |